172 related articles for article (PubMed ID: 19694612)
41. Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug.
Surwase SS; Munot NM; Idage BB; Idage SB
Drug Deliv Transl Res; 2017 Jun; 7(3):416-427. PubMed ID: 28324320
[TBL] [Abstract][Full Text] [Related]
42. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
Paolino D; Licciardi M; Celia C; Giammona G; Fresta M; Cavallaro G
Eur J Pharm Biopharm; 2012 Sep; 82(1):94-102. PubMed ID: 22705641
[TBL] [Abstract][Full Text] [Related]
43. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Sloat BR; Sandoval MA; Li D; Chung WG; Lansakara-P DS; Proteau PJ; Kiguchi K; DiGiovanni J; Cui Z
Int J Pharm; 2011 May; 409(1-2):278-88. PubMed ID: 21371545
[TBL] [Abstract][Full Text] [Related]
45. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
46. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro.
Li JM; Chen W; Wang H; Jin C; Yu XJ; Lu WY; Cui L; Fu DL; Ni QX; Hou HM
Acta Pharmacol Sin; 2009 Sep; 30(9):1337-43. PubMed ID: 19730429
[TBL] [Abstract][Full Text] [Related]
47. Mesoporous silica nanoparticles with bilayer coating of poly(acrylic acid-co-itaconic acid) and human serum albumin (HSA): A pH-sensitive carrier for gemcitabine delivery.
Pourjavadi A; Tehrani ZM
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():782-90. PubMed ID: 26838909
[TBL] [Abstract][Full Text] [Related]
48. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
49. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
50. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
Jordheim LP; Cros E; Gouy MH; Galmarini CM; Peyrottes S; Mackey J; Perigaud C; Dumontet C
Clin Cancer Res; 2004 Aug; 10(16):5614-21. PubMed ID: 15328204
[TBL] [Abstract][Full Text] [Related]
51. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
52. Magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil delivery systems for active targeting.
Arias JL; Gallardo V; Ruiz MA; Delgado AV
Eur J Pharm Biopharm; 2008 May; 69(1):54-63. PubMed ID: 18164927
[TBL] [Abstract][Full Text] [Related]
53. Iron/ethylcellulose (core/shell) nanoplatform loaded with 5-fluorouracil for cancer targeting.
Arias JL; López-Viota M; Delgado AV; Ruiz MA
Colloids Surf B Biointerfaces; 2010 May; 77(1):111-6. PubMed ID: 20153955
[TBL] [Abstract][Full Text] [Related]
54. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.
Parsian M; Unsoy G; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Eur J Pharmacol; 2016 Aug; 784():121-8. PubMed ID: 27181067
[TBL] [Abstract][Full Text] [Related]
55. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
56. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
[TBL] [Abstract][Full Text] [Related]
57. Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
Marañda E; Szmigielska A; Robak T
Cancer Invest; 1999; 17(2):95-101. PubMed ID: 10071592
[TBL] [Abstract][Full Text] [Related]
58. Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies.
Chen G; Svirskis D; Wen J
J Pharm Pharmacol; 2015 Nov; 67(11):1528-36. PubMed ID: 26369422
[TBL] [Abstract][Full Text] [Related]
59. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
[TBL] [Abstract][Full Text] [Related]
60. Micellar nanoparticles loaded with gemcitabine and doxorubicin showed synergistic effect.
Liu D; Chen Y; Feng X; Deng M; Xie G; Wang J; Zhang L; Liu Q; Yuan P
Colloids Surf B Biointerfaces; 2014 Jan; 113():158-68. PubMed ID: 24077114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
